𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation

✍ Scribed by Daniel Seehofer; Nada Rayes; Thomas Berg; Ruth Neuhaus; Andrea R. Müller; Uwe Hopf; Wolf Otto Bechstein; Peter Neuhaus

Book ID
110915820
Publisher
Springer
Year
2000
Tongue
English
Weight
652 KB
Volume
13
Category
Article
ISSN
0934-0874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of long-term lamivudine treatment o
Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation
✍ Hyun Young Woo; Jong Young Choi; Jeong Won Jang; Chan Ran You; Si Hyun Bae; Seun 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract In this study, the long‐term (>3 years) efficacy of combination therapy for hepatitis B virus (HBV) recurrence and the associated factors were investigated. One hundred and sixty‐five consecutive HBsAg‐positive patients (92 with liver cirrhosis, 73 with hepatocellular carcinoma; HCC) wh

Multicenter study of lamivudine therapy
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
✍ Robert Perrillo; Jorge Rakela; Jules Dienstag; Gary Levy; Paul Martin; Teresa Wr 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Hepatitis B after liver transplantation is often fatal, and no proven medical therapy exists for this condition. We chose to study the potential efficacy of lamivudine therapy for patients with chronic hepatitis B after liver transplantation. Fifty-two patients with chronic hepatitis B after liver t

Prevention of hepatitis B recurrence aft
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis
✍ Shusen Zheng; Yaomin Chen; Tingbo Liang; Anwei Lu; Weilin Wang; Yan Shen; Min Zh 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low-dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had